HCC or ICC patients with a lower level of circRNA_101505 or circ-SMARCA5 have a shorter overall survival period than patients with higher levels of these circRNAs [31, 160]. This evidence concerns the gene SMARCA5 and intrahepatic cholangiocarcinoma.